Contemporary Targeted Therapies in Rheumatology
eBook - ePub

Contemporary Targeted Therapies in Rheumatology

  1. 636 pages
  2. English
  3. ePUB (mobile friendly)
  4. Available on iOS & Android
eBook - ePub

Contemporary Targeted Therapies in Rheumatology

About this book

Targeted therapies of rheumatic diseases have become a reality and have completely changed patient care as well as patient expectations. Initial success with therapies aimed at blocking TNF and IL-1 has stimulated the development of additional targeted approaches focused on other cytokines as well as specific cells and pathways involved in the path

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Contemporary Targeted Therapies in Rheumatology by Josef S. Smolen, Peter E. Lipsky, Josef S. Smolen,Peter E. Lipsky in PDF and/or ePUB format, as well as other popular books in Medicine & Rheumatology, Orthopedics & Prosthetics. We have over one million books available in our catalogue for you to explore.

Table of contents

  1. Cover
  2. Half Title
  3. Title Page
  4. Copyright Page
  5. Table of Contents
  6. Contributors
  7. 1 T cells   overview   update
  8. 2 Pathways of T-cell costimulation
  9. 3 Regulatory T cells
  10. 4 B-cell antigen receptor signaling and autoimmunity
  11. 5 Macrophages in rheumatoid arthritis
  12. 6 Dendritic cells
  13. 7 Osteoclasts
  14. 8 Cell contact dependence of inflammatory events
  15. 9 Toll-like receptors: possible targets for novel treatments for rheumatoid arthritis
  16. 10 Cadherin-11 mediates synovial lining organization: a new therapeutic targetin inflammatory arthritis
  17. 11 TNF-a
  18. 12 Update on interleukin-6
  19. 13 Interleukin-13
  20. 14 Biology of interleukin-15
  21. 15 Interleukin-17: a new target in arthritis
  22. 16 The role of interleukin-18 in inflammation
  23. 17 Interleukin-21
  24. 16 The biology of human interleukin-32
  25. 19 The interferons
  26. 20 Osteoprotegerin
  27. 21 Update: inflammatory, angiogenic, and homeostatic chemokines and their receptors
  28. 22 New developments in NF-kB
  29. 23 Roles of the JAK-STAT signaling pathways in rheumatoid arthritis
  30. 24 Suppressor of cytokine signaling (SOCS) proteins as therapeutic targets inrheumatoid arthritis
  31. 25 Wnt signaling for targeted therapies in rheumatology
  32. 26 Inflammatory mediators: update on cyclooxygenases andprostaglandin synthases
  33. 27 Complement and pregnancy loss
  34. 28 Matrix metalloproteinases
  35. 29 MMPs and ADAMs as targets for therapies in arthritis
  36. 30 Update on proinflammatory cytokine blockade in rheumatoid arthritis
  37. 31 Targeting interleukin-1 in rheumatic diseases
  38. 32 Update on targeted therapy in psoriatic arthritis
  39. 33 Spondyloarthritides
  40. 34 Early Arthritis
  41. 35 Juvenile arthritis
  42. 36 Update   systemic lupus erythematosus
  43. 37 Vasculitis
  44. 38 Myositis
  45. 39 TNF blockade in orphan rheumatic diseases
  46. 40 Overview of the safety of TNF inhibitors
  47. 41 Anti-CD20 to further targeted therapies in rheumatology
  48. 42 Targeting B-lymphocyte stimulator (BLyS) in immune-based rheumaticdiseases: a therapeutic promisewaiting to be fulfilled
  49. 43 Anti-CD3 antibody   a history of successful immune interventions
  50. 44 Alefacept
  51. 45 Clinical targeting of interleukin-15
  52. 46 Clinical prospects of MAPK inhibitors
  53. 47 Clinical prospects of NF-kB inhibitors to further targeted therapies in rheumatology
  54. 48 Outcomes assessment in rheumatic disease
  55. Index